Natixis Fibrogen Inc Transaction History

Natixis

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.79 - $2.83 $39,421 - $141,217	-49,900 Reduced 62.45%	30,000 $25,000
Q2 2023 Aug 11, 2023	BUY	$2.49 - $20.59 $198,951 - $1.65 Million	79,900 New	79,900 $215,000
Q1 2022 May 13, 2022	SELL	$12.02 - $16.79 $1.41 Million - $1.98 Million	-117,675 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$9.93 - $15.39 $819,463 - $1.27 Million	-82,524 Reduced 41.22%	117,675 $1.66 Million
Q3 2021 Nov 12, 2021	BUY	$10.18 - $26.64 $111,857 - $292,720	10,988 Added 5.81%	200,199 $2.05 Million
Q4 2020 Feb 12, 2021	SELL	$37.09 - $48.97 $1.23 Million - $1.63 Million	-33,199 Reduced 14.93%	189,211 $7.02 Million
Q3 2020 Nov 12, 2020	BUY	$40.47 - $45.5 $9 Million - $10.1 Million	222,410 New	222,410 $9.15 Million
Q4 2018 Feb 14, 2019	SELL	$37.97 - $60.16 $513,088 - $812,942	-13,513 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$56.3 - $67.25 $760,781 - $908,749	13,513 New	13,513 $821,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.